Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Fosun Pharma's In-licensed COVID-19 Vaccine Scores 90% Efficacy in US-EU Tests
Fosun Pharma's (SHA: 600196; HK: 02196) in-licensed COVID-19 vaccine reported 90% efficacy in US-EU Phase III tests, which were conducted by Pfizer (NYSE: PFE) and Germany's BioNTech (NSDQ: BNTX). In March, Fosun acquired
Fosun expects it will need to conduct only a small bridging trial to secure
“This is a victory for science, a victory for global cooperation … it is a landmark moment marking the light at the end of the tunnel in our fight against the novel coronavirus,” said Guo Guangchang, the chairman of Fosun Pharma's parent, the conglomerate Fosun International in a blog. “Currently, Fosun Phama is communicating with regulators, and is striving to be able to start bridging clinical trials and to launch BNT162b2 in mainland
The Pfizer-BioNTech Phase III trial, which started in July, has so far enrolled 43,500 patients, dosing each patient twice with a one month interval between the two. In three weeks, all of the 43,500 enrollees will have completed two months after the second dose. If no serious adverse effects surface in that time, Pfizer will file for approval.
After the vaccine is approved in
See our other articles on Fosun Pharma, Pfizer and BioNTech.
Disclosure: none.
Fosun Pharma's in-licensed COVID-19 vaccine reported 90% efficacy in US-EU Phase III tests, which were conducted by Pfizer and Germany's BioNTech.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China